% | $
Quotes you view appear here for quick access.

Insmed Incorporated Message Board

  • fdaplayq fdaplayq Oct 21, 2013 10:49 AM Flag

    Unknown RDHL (MC $61 M) FDA deicison on Feb 3 // 2 more NDA filings in 2014 // Float 4 M = 500%++ Potential

    Brutal Underpriced Gem..

    Redhill Biopharma (RDHL)

    Market Cap: $60 M
    Cash: $14.7 M
    Burn-rate : ~$10 per Year

    Shares Out: 6.3 M ( Management holds over 2.6 M shares )
    Float: 4 M

    RHB-103 - An oral thin film formulation of rizatriptan, for the treatment of acute migraine, with a U.S. NDA filed and accepted for review by the FDA and a PDUFA date of February 3, 2014.Market Size: Worldwide triptan market for the treatment of migraine exceeds $2 billion*

    RHB-102 - A once-daily formulation of ondansetron, for the treatment of chemotherapy and radiotherapy-induced nausea and vomiting, planned for U.S. NDA submission during the first quarter of 2014.Market Size: Worldwide market for serotonin (5-HT3) receptor inhibitors is estimated at $900 million**

    RHB-101 - A once-daily formulation of carvedilol, for the treatment of congestive heart failure and high blood pressure, planned to be submitted for a U.S. New Drug Application (NDA) and a Marketing Authorization Application (MAA) in Europe during the second half of 2014.Market Size: Worldwide target market of $500 million**

    RHB-105 - A combination therapy for Helicobacter pylori infection, planned to commence a phase II/III trial in the third quarter of 2013.Market Size: U.S. market is estimated at approximately $1-1.5 billion*

    RHB-104 - A combination therapy for the treatment of Crohn’s disease, with a phase III clinical study underway.Market Size: Worldwide market exceeded $3.5 billion in 2012

    RHB-104 - A combination therapy for the treatment of Multiple Sclerosis (MS), with a Phase IIa proof of concept trial currently underway.Market Size: Worldwide market of over $14 billion*

    RHB-104 - A combination therapy for the treatment of Rheumatoid Arthritis, with a planned Phase IIa study.Market Size: Worldwide market of over $20 billion*

    RHB-106 - An encapsulated formulation for bowel preparation (laxative) ahead of colonoscopy and other GI procedures.Market Size: Worldwide market is estimated at approximately $1.4 billion

13.76-0.24(-1.71%)4:00 PMEDT